

Cryo Cell International Inc. (CCEL)

NYSE; healthcare; SIC 8090, Services-Misc Health & Allied Services, NEC; CIK 0000862692

Cryo Cell International Inc. CCEL; healthcare	
Grade	C/D A B C D E on the C/D boundary of 371 graded peers percentile 57.6; sampling error 2.5 points; lower is stronger
Rank	214 of 371
Profitability	B/C percentile 39.1
Solvency	D percentile 68.1
Growth and financing	C percentile 44.8
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$61.7M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	11 of 14
Graded from	filings received through Feb 27, 2026 224 days before the rescans; latest periodic filing 10-Q received Jul 15, 2026
Last close	\$3.76 2026-10-05; market equity \$30.3M
Price used in grade	None



C/D, the tortoise

on the C/D boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: C from May 21, 2026, C/D from Aug 21, 2026, C from Sep 26, 2026, C/D from Oct 9, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Cryo-Cell International, Inc. (the "Company" or "Cryo-Cell") is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System ("PrepaCyte CB") units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 39.1						
Gross profitability		39.2%	32.2%	34.2	372	2025-11-30
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(12.5%)	(6.6%)	35.1	811	2025-11-30
Gross margin stability, five years		2.8 pts	2.8 pts	47.9	243	2025-11-30
Solvency, sleeve percentile 68.1						
Twelve-month failure probability		0.62%	0.07%	85.4	248	2026-05-31
Altman Z double-prime		(3.07)	(0.31)	49.3	756	2025-11-30
Net debt to EBITDA		5.47x	1.82x	85.1	75	2025-11-30
Interest coverage		0.23x	(4.51x)	27.5	81	2025-11-30
Current ratio		0.59x	2.96x	93.1	839	2025-11-30
Growth and financing, sleeve percentile 44.8						
Revenue growth, three-year compound		1.3%	10.0%	68.8	415	2025-11-30
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(1.7%)	2.1%	54.9	704	2025-11-30
Net share issuance, one year		(0.3%)	2.5%	10.7	634	2026-02-28

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
209	AdaptHealth Corp. (AHCO)	56.2	C	
210	Inogen Inc. (INGN)	56.5	C	fortress balance sheet
211	Cooper Companies, Inc. (COO)	56.8	C	

212	Aquestive Therapeutics, Inc. (AQST)	57.0	C
213	Tango Therapeutics, Inc. (TNGX)	57.3	C dilution
214	Cryo Cell International Inc. (CCEL) <	57.6	C/D
215	electroCore, Inc. (ECOR)	57.8	C/D
216	Rocket Pharmaceuticals, Inc. (RCKT)	58.1	C/D degenerate inputs
217	Prestige Consumer Healthcare Inc. (PBH)	58.4	C/D
218	Becton Dickinson & Co. (BDX)	58.6	C/D
219	Option Care Health, Inc. (OPCH)	58.9	C/D

What the price implies

at the 2026-10-05 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(9.5%)	8.0%	40
Distance from 52-week high	(8.8%)	(31.4%)	86
EBIT to enterprise value	1.2%	(1.5%)	58
Free cash flow yield	15.6%	(1.0%)	95
Book value to price	(0.53)	0.28	3
Sales to price	0.94	0.31	82
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.31)	(0.14)	40

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-11-30	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$507,302
Operating cash flow, four quarters	\$6.3M
Months of runway	not finite
Days since last periodic filing	86 (10-Q received Jul 15, 2026)
Median daily dollar volume, 63 sessions	\$38,701

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$31.6M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$7.4M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
3	assets	us-gaap:Assets	\$61.7M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
4	operating income	us-gaap:OperatingIncomeLoss	\$482,394	2025-11-30	2026-02-27	10-K	0001193125-26-083096
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNondeductible	\$12.5M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$92,232	2025-11-30	2026-02-27	10-K	0001193125-26-083096
7	total debt	us-gaap:LongTermDebt	\$8.4M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
8	book equity	us-gaap:StockholdersEquity	-\$18.6M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$319,031	2025-11-30	2026-02-27	10-K	0001193125-26-083096
10	total debt	us-gaap:LongTermDebt	\$8.5M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
11	book equity	us-gaap:StockholdersEquity	-\$13.2M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$560,960	2024-11-30	2026-02-27	10-K	0001193125-26-083096

13	net income	us-gaap:NetIncomeLoss	-\$2.4M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.5M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
15	assets	us-gaap:Assets	\$64.7M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
16	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$32.0M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$7.9M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
18	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$31.3M	2023-11-30	2025-02-28	10-K	0000950170-25-030138
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$8.4M	2023-11-30	2025-02-28	10-K	0000950170-25-030138
20	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$30.3M	2022-11-30	2024-02-28	10-K	0000950170-24-022275
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$8.8M	2022-11-30	2024-02-28	10-K	0000950170-24-022275
22	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$28.9M	2021-11-30	2023-02-28	10-K	0000950170-23-005220
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$9.0M	2021-11-30	2023-02-28	10-K	0000950170-23-005220
24	current assets	us-gaap:AssetsCurrent	\$11.8M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
25	current liabilities	us-gaap:LiabilitiesCurrent	\$19.8M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$38.4M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
27	liabilities	us-gaap:Liabilities	\$80.3M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$985,242	2025-11-30	2026-02-27	10-K	0001193125-26-083096
29	interest expense	us-gaap:InterestExpense	\$2.1M	2025-11-30	2026-02-27	10-K	0001193125-26-083096
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$230,475	2025-11-30	2026-02-27	10-K	0001193125-26-083096
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$6.0M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.4M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.9M	2023-11-30	2025-02-28	10-K	0000950170-25-030138
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.8M	2023-11-30	2025-02-28	10-K	0000950170-25-030138
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.6M	2022-11-30	2024-02-28	10-K	0000950170-24-022275
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12.2M	2022-11-30	2024-02-28	10-K	0000950170-24-022275
37	current assets	us-gaap:AssetsCurrent	\$12.6M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
38	current liabilities	us-gaap:LiabilitiesCurrent	\$21.6M	2024-11-30	2026-02-27	10-K	0001193125-26-083096
39	assets	us-gaap:Assets	\$61.2M	2023-11-30	2025-02-28	10-K	0000950170-25-030138
40	assets	us-gaap:Assets	\$64.9M	2022-11-30	2024-02-28	10-K	0000950170-24-022275
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,055,150	2026-02-28	2026-02-27	10-K	0001193125-26-083096
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,082,159	2025-02-28	2025-02-28	10-K	0000950170-25-030138